Is the new coronal vaccine more effective by inhalation than by intramuscular injection? UK to do human trials

British scientists will start a small study to see if the two new coronal vaccines being developed are safer and more effective when inhaled rather than injected. < / P > < p > the two vaccines were developed by Imperial College and Oxford University respectively, and clinical trials of intramuscular injection are being carried out. Thirty volunteers were invited to take part in the inhalation experiment. “We have evidence that influenza vaccination through nasal spray can protect people from influenza attacks and help reduce the spread of disease,” said Dr. Chris Chiu, who led the study at Imperial College London in September 14th.

, he suggested novel coronavirus pneumonia may also be prevented. “Compared with intramuscular vaccines, it is important that we explore whether direct action on the respiratory tract can also work.” < / P > < p > scientists say that the injection of a new crown vaccine into the respiratory tract may trigger a local and more specific immune response than a systemic immune response induced by intramuscular injection. In addition, according to previous studies, the dose of vaccine required to initiate an immune response is smaller than that of an intramuscular injection. < p > < p > the Imperial College vaccine uses a synthetic genetic code chain based on the virus. Once injected into the muscle, the body’s own cells are instructed to replicate the spike protein on the new coronavirus. The novel coronavirus pneumonia is expected to trigger immune response in turn, and the body can resist any infection of the new crown pneumonia in the future. In contrast, the Oxford University vaccine azd1222 uses a harmless virus that carries the spike protein of the new coronavirus into the body to trigger an immune response. The azd1222 vaccine has been authorized by pharmaceutical giant AstraZeneca for further development, production and supply. On September 8, AstraZeneca suspended a large-scale vaccination test because a British subject had “a disease that may not be explained”; on the 12th, the trial was resumed after an independent committee reviewed the relevant safety data. Home